Pharmaceutical company AstraZeneca will be supplying the United States with up to half a million extra doses of its experimental antibody-based COVID-19 therapy, Reuters reported.
The treatment has not been approved by U.S. regulators.
Unlike a vaccine that is intended to prevent a COVID-19 infection, the treatment treats the illness, Reuters reported.
It has shown promise combating the variants of COVID-19, Bloomberg reported.
>> Related: Moderna begins testing COVID-19 vaccine for children
The drugmaker said the 500,000 additional doses are in addition to the 200,000 doses that were agreed upon in October.
The deal will cost as much as $726 million, Bloomberg reported.
The shipment is contingent on an emergency use approval by the Food and Drug Administration.
The treatment, AZD7442, is in late-stage trials, Reuters reported.
More coronavirus pandemic coverage:
>> Coronavirus vaccines: CDC separates myths from facts
>> Coronavirus: Should we be wearing two masks when we go out in public?
>> Coronavirus: How long between exposure to the virus and the start of symptoms?
>> Wash your masks: How to clean a cloth face covering
>> Fact check: Will masks lower the oxygen level, raise the carbon dioxide in your blood?
>> How to not let coronavirus pandemic fatigue set in, battle back if it does
